Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 16OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 428Neoplasms 296Breast Neoplasms 296Colorectal Neoplasms 241Neoplasm Metastasis 196Ovarian Neoplasms 171Lung Neoplasms 149Recurrence 148Prostatic Neoplasms 146Pancreatic Neoplasms 141Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 114Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Monoclonal Gammopathy of Undetermined Significance × Clear all
NCT06140524 2026-06-04

LINKER-MGUS1

Regeneron Pharmaceuticals

Phase 2 Recruiting
116 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡